NO20061625L - Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger - Google Patents

Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger

Info

Publication number
NO20061625L
NO20061625L NO20061625A NO20061625A NO20061625L NO 20061625 L NO20061625 L NO 20061625L NO 20061625 A NO20061625 A NO 20061625A NO 20061625 A NO20061625 A NO 20061625A NO 20061625 L NO20061625 L NO 20061625L
Authority
NO
Norway
Prior art keywords
prodrugs
urinary incontinence
prevention
treatment
gaba analogues
Prior art date
Application number
NO20061625A
Other languages
English (en)
Norwegian (no)
Inventor
Ronald William Barrett
Original Assignee
Xenopor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenopor Inc filed Critical Xenopor Inc
Publication of NO20061625L publication Critical patent/NO20061625L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061625A 2003-09-11 2006-04-10 Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger NO20061625L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50258503P 2003-09-11 2003-09-11
US50521003P 2003-09-22 2003-09-22
US51228803P 2003-10-17 2003-10-17
US53874804P 2004-01-22 2004-01-22
PCT/US2004/029944 WO2005025562A1 (en) 2003-09-11 2004-09-13 Treating and/or preventing urinary incontinence using prodrugs of gaba analogs

Publications (1)

Publication Number Publication Date
NO20061625L true NO20061625L (no) 2006-06-12

Family

ID=34317683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061625A NO20061625L (no) 2003-09-11 2006-04-10 Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger

Country Status (11)

Country Link
US (2) US7700652B2 (enExample)
EP (1) EP1670451A4 (enExample)
JP (1) JP2007505149A (enExample)
KR (1) KR20060119971A (enExample)
AU (1) AU2004272111A1 (enExample)
CA (1) CA2537837A1 (enExample)
IL (1) IL174409A0 (enExample)
MX (1) MXPA06002731A (enExample)
NO (1) NO20061625L (enExample)
NZ (1) NZ545884A (enExample)
WO (1) WO2005025562A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
KR101096480B1 (ko) * 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EA200970487A1 (ru) * 2006-12-08 2009-12-30 Ксенопорт, Инк. Применение пролекарств аналогов гамк для лечения заболеваний
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
JP2010515754A (ja) * 2007-01-11 2010-05-13 ゼノポート，インコーポレイティド Ｒ−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009087682A2 (en) * 2007-12-28 2009-07-16 Intas Pharmaceuticals Limited Stabilized injectable formulation of pregabalin
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
JP5563483B2 (ja) * 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
NZ594648A (en) * 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
CZ286106B6 (cs) 1992-05-20 2000-01-12 Northwestern University Analogy GABA a L-glutamové kyseliny
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
CA2244708A1 (en) 1996-02-07 1997-08-14 Justin S. Bryans Novel cyclic amino acids as pharmaceutical agents
IL125364A0 (en) 1996-03-14 1999-03-12 Warner Lambert Co Novel bridged cyclic amino acids and pharmaceutical compositions containing them
PL185991B1 (pl) 1996-03-14 2003-09-30 Warner Lambert Co Nowe podstawione cykliczne aminokwasy i kompozycja farmaceutyczna
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
AU733896B2 (en) 1996-10-23 2001-05-31 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
CU23048A3 (es) 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
EP1400526A3 (en) 1997-12-16 2004-03-31 Warner-Lambert Company LLC ((cyclo)alkyl substituted)- gamma -aminobutyric acid derivatives (=Gaba analogues), their preparation and their use in the treatment of neurological disorders
CA2304967C (en) 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1475371A1 (en) 1997-12-16 2004-11-10 Warner-Lambert Company LLC 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders
KR20010043831A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
KR20010075064A (ko) 1998-09-14 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 분지쇄 알킬 피롤리딘-3-카르복실산
AU1602100A (en) 1998-11-25 2000-06-13 Warner-Lambert Company Improved gamma amino butyric acid analogs
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DE60044160D1 (de) 1999-04-08 2010-05-20 Warner Lambert Co Behandlung von Inkontinenz
DE60034344T2 (de) * 1999-07-22 2008-01-10 University Of Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
ATE390133T1 (de) 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002044324A2 (en) 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP1343805A4 (en) 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
US6683112B2 (en) 2000-10-24 2004-01-27 Andrx Corporation Gabapentin prodrugs and formulations
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PT1404324E (pt) * 2001-06-11 2008-03-05 Xenoport Inc Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002316237A1 (en) 2001-06-13 2002-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain
DE60208065T2 (de) 2001-08-09 2006-07-13 Eli Lilly And Co., Indianapolis Cyclohept'b! indolderivate als spla2-inhibitoren
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
WO2004058168A2 (en) 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
DK1492519T3 (da) 2003-03-21 2007-03-05 Dynogen Pharmaceuticals Inc Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer
MXPA05010515A (es) 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
KR101140559B1 (ko) 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
DK1716115T3 (da) 2003-12-30 2013-05-27 Xenoport Inc Syntese af acyloxyalkylcarbamat-prodrug og mellemprodukter deraf
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US20060222700A1 (en) 2005-04-05 2006-10-05 Groenewoud Pieter J Tablet and capsule form of liquid active ingredient
ZA200806138B (en) 2005-12-16 2009-11-25 Hanmi Pharm Ind Co Ltd Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
MX2009005114A (es) 2006-11-14 2009-07-16 Xenoport Inc Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
EA200970487A1 (ru) 2006-12-08 2009-12-30 Ксенопорт, Инк. Применение пролекарств аналогов гамк для лечения заболеваний
JP2010515754A (ja) 2007-01-11 2010-05-13 ゼノポート，インコーポレイティド Ｒ−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法

Also Published As

Publication number Publication date
AU2004272111A1 (en) 2005-03-24
JP2007505149A (ja) 2007-03-08
IL174409A0 (en) 2011-08-01
MXPA06002731A (es) 2006-06-05
WO2005025562A1 (en) 2005-03-24
EP1670451A4 (en) 2009-10-21
US20100166825A1 (en) 2010-07-01
US20050090550A1 (en) 2005-04-28
CA2537837A1 (en) 2005-03-24
NZ545884A (en) 2010-01-29
KR20060119971A (ko) 2006-11-24
EP1670451A1 (en) 2006-06-21
US7700652B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
NO20061625L (no) Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger
WO2005027850A3 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
WO2007087468A3 (en) Adiponectin for treatment of various disorders
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
DK2029602T3 (da) Triazolopyrazinforbindelser, der kan anvendes til behandling af degenerative og inflammatoriske sygdomme
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
ZA200806778B (en) N-Hydroxyacrylamide compounds
NO20081050L (no) Kaspaseinhibitor-prodroger
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
WO2008073779A3 (en) Compositions and methods for treating seizures
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application